Industry Daily Summary
Industry Daily Summary: What Happened on November 19, 2026
Johnson & Johnson agrees to buy Ollin for up to $3.3 billion
California biopharma layoffs affected at least 1,176 workers, while AbbVie and DISCO agreed to a cancer-drug discovery deal worth up to $2.5 billion.
Today in brief
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, with as much as $1.125 billion more tied to regulatory and commercial milestones.1 Ollin’s Phase III antibody OLN324 targets retinal diseases.1 BioSpace counted at least 1,176 workers affected by cuts announced or projected by 24 California biopharma companies this year.2
AbbVie will pay DISCO Pharmaceuticals $40 million upfront to discover cancer drugs, with additional payments and royalties possible.3
Johnson & Johnson adds a Phase III eye drug through an Ollin buyout
Johnson & Johnson agreed on November 16 to acquire Ollin Biosciences for $2.2 billion upfront, plus as much as $1.125 billion in regulatory and commercial milestones.1 Ollin’s lead candidate, OLN324, is an investigational bispecific antibody in Phase III for wet age-related macular degeneration and diabetic macular edema.1
OLN324’s clinical differentiation, regulatory path and commercial adoption remain uncertain.1 Separately, Johnson & Johnson announced $750 million in development financing from Blackstone Life Sciences, along with contingent payments and royalties.1
At least 1,176 workers affected by California biopharma cuts
BioSpace counted at least 1,176 workers affected by layoffs announced or projected by 24 California biopharma companies during 2026.2 Nine companies were cutting at least half their workforces, and two had closed.2
Gilead had the largest reported California cuts, affecting 193 workers, including 108 Arcellx employees laid off in June.2 Artiva Biotherapeutics said it would stop developing its lead candidate and cut about 94% of its employees after two patient deaths and concerns about response durability.2 In August, aTyr Pharma said it would cut about 60% of its staff to focus resources on efzofitimod for interstitial lung disease.2
AbbVie offers DISCO up to $2.5 billion for cancer-drug discovery
AbbVie will pay DISCO Pharmaceuticals $40 million upfront for cancer-drug discovery research.3 DISCO may also receive as much as $2.5 billion in payments tied to options, development and other milestones, plus tiered royalties on global net sales.3
After specified research, AbbVie may take exclusive licenses to selected programs for further development.3 DISCO’s platform searches for pairs of proteins found together on cancer cells but less often together on healthy tissue.3
Also worth knowing
-
Genomics Limited and Vertex Pharmaceuticals extended their drug-discovery partnership by four years. Genomics says the agreement could exceed $220 million through milestones and royalties.45
-
Merck and Isomorphic Labs will search for small-molecule candidates against an undisclosed cancer target. Merck will handle development, manufacturing and commercialization of any resulting products.6
Also published
- MHRA appoints senior NHS executive as new Chief Finance and Commercial Officer MHRA
- Multiple sclerosis market expected to reach $33.0bn across the 7MM by 2034 Pharmaceutical Technology
- Progress with NHS England pilots of alternative funding approaches pharmaphorum
- A new chapter for GeneCore EMBL
- Ramping up: 3 biotechs growing their workforce after series C raises BioSpace